Skip to main content

Table 2 Anti-phospholipid antibody (aPL) positives by line immunoassay (LIA) and consensus criteria enzyme-linked immunosorbent assay (ELISA) in 95 subjects including 34 patients with anti-phospholipid syndrome (APS), 41 with systemic autoimmune rheumatic disease (SARD), and 20 healthy subjects (children) (HS) as control groups

From: Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases

ELISA LAC TP aD1/aD4–5 LIA
  ACL aβ2GPI Any aPL aCL aPA aPC aPE aPG aPI aPS aAnV aβ2GPI aPT Any aPL
G M G M G M G M G M G M G M G M G M G M G M G M
APS
n = 34 		24 21 30 18 31 24 14 28 27 13 24 10 0 0 0 0 18 1 7 2 30 16 2 5 27 17 17 5 33
SARD
n = 41 		18*** 19 25** 23 33 18*** 8 26 26 12 22 8 0 0 0 0 4* 0 3 2 27*** 9*** 0 3 22*** 12 7** 3 32
HS
n = 20 		NA 0# 0# 1## 1# NA NA NA 1# 0## 0# 0#### 0 0 0 1 0# 1 0#### 0 0# 0## 0 0 1# 0# 1## 1 3#
  1. Comparison of APS vs SARD: *p < 0.001, **p < 0.01, ***p < 0.05
  2. Comparison of APS vs HC: #p < 0.0001, ##p < 0.001, ###p < 0.01, ####p < 0.05
  3. LAC and TP testing was conducted for 33 APS and 39 SARD patients only
  4. aβ2GPI anti-beta2 glycoprotein I, aCL anti-cardiolipin, aD1 anti-domain 1, aD4–5 anti-domains 4 and 5, aPA anti-phosphatidic acid, aPC anti-phosphatidylcholine, aPE anti-phosphatidylethanolamine, aPG anti-phosphatidylglycerol, aPI anti-phosphatidylinositol, aPS anti-phosphatidyl-serine, aAnV anti-annexin V, aPT anti-prothrombin, LAC lupus anti-coagulant, TP triple positivity (aCL positive, aβ2GPI positive, LAC positive), NA not available
Back to article page

Autoimmunity Highlights

ISSN: 2038-3274

Contact us